Clozapine Restores Function in Soldiers with Refractory PTSD, Recent Case Series
A recent case series shows that clozapine can help soldiers with severe, treatment-resistant post-traumatic stress disorder successfully return to work and family life while significantly reducing aggression and suicidality. This atypical antipsychotic offers a promising new path for patients with combat-related trauma who have failed standard therapies.
These case series findings were published in 2026 in the Indian Journal of Psychological Medicine by lead author Roshan Monaragala and his psychiatric research team.
Combat-induced trauma notoriously produces highly chronic, disabling trajectories of post-traumatic stress disorder (PTSD) that show extreme resistance to first-line pharmacotherapies and trauma-focused psychotherapies. Since up to forty percent of these suffering patients achieve only partial remission with standard treatments, clinicians urgently require alternative, evidence-based psychopharmacological strategies. Exploring off-label clozapine in these refractory, non-psychotic cohorts offers a promising pathway to address profound functional impairment and lower premature mortality risks.
The clinical cohort comprised seven young military soldiers presenting with chronic combat trauma, severe sleep disturbances, aggression, and recurrent suicidality who underwent clinical investigations and were subsequently diagnosed with complex post-traumatic stress disorder (CPTSD) by a consultant psychiatrist using International Classification of Diseases criteria. Having failed twelve months of standard antidepressant, second-generation antipsychotic, and trauma-focused psychotherapeutic regimens, these patients received titrated clozapine between 125 and 300 milligrams daily, resulting in significant symptom reduction and occupational reintegration for four responders during subsequent follow-up, while three discontinued due to intolerable adverse effects and experienced immediate clinical relapse.
Clozapine’s therapeutic efficacy in treatment-resistant cases is biochemically justified by its broad-spectrum receptor affinity, which targets and modulates serotonin, dopamine, muscarinic, histaminergic, and alpha-1 adrenergic pathways to correct central neurotransmitter dysregulation. Additionally, its potent antihistaminergic properties induce crucial sedation that directly repairs disrupted sleep architecture and nightmare intensity, while clinicians must note that concurrent tobacco smoking significantly accelerates its metabolism via cytochrome P450 1A2 (CYP1A2) liver enzyme induction.
These clinical outcomes demonstrate that clozapine is a valuable therapeutic alternative for treating refractory combat trauma when the benefits of restoring functioning outweigh benign medication risks. Furthermore, this series successfully challenges the historical overestimation of clozapine's danger, emphasizing the critical need for prospective, randomized controlled trials to systematically establish standardized dosing guidelines and treatment durations.
Reference
Monaragala, R., Chandradasa, M., & Kuruppuarachchi, K. A. L. A. (2026). Clozapine for Post-traumatic Stress Disorder: Redefining Treatment Resistance in Soldiers Without Psychosis. Indian Journal of Psychological Medicine, 2026:1–5.
